Original paper
Lenvatinib and Cu2−xS nanocrystals co-encapsulated in poly(d ,l -lactide-co-glycolide) for synergistic chemo-photothermal therapy against advanced hepatocellular carcinoma
Abstract
Lenvatinib (LT) is gradually replacing sorafenib as an alternative targeted drug against advanced hepatocellular carcinoma (HCC). However, the anticancer effects of LT are still limited because of its low cytotoxicity, multidrug resistance (MDR), and tumor relapse. Herein, we constructed a smart biophotonic nanoplatform to overcome the barriers preventing high performance. LT and copper sulfide nanocrystals (Cu2-xS NCs) with excellent...
Paper Details
Title
Lenvatinib and Cu2−xS nanocrystals co-encapsulated in poly(d ,l -lactide-co-glycolide) for synergistic chemo-photothermal therapy against advanced hepatocellular carcinoma
Published Date
Jan 1, 2021
Volume
9
Issue
48
Pages
9908 - 9922
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History